| affect central nervous … | 0.55 |
| affect young adults | 0.52 |
| affect woman | 0.52 |
| affect the brain | 0.47 |
| affect spinal cord | 0.46 |
| affect the brain and sp… | 0.45 |
| affect more than 2.3 mi… | 0.42 |
| attack central nervous … | 0.41 |
| affect people | 0.40 |
| affect optic nerves | 0.39 |
| More » |
| pain | 0.35 |
| person’s immune system | 0.34 |
| inflammation | 0.32 |
| vision loss | 0.30 |
| numbness | 0.30 |
| impaired coordination | 0.25 |
| fatigue | 0.23 |
| stiffness | 0.16 |
| tremor | 0.16 |
| devastating impact | 0.30 |
| known cause | 0.21 |
| unpredictable, disabling | 0.47 |
| rare | 0.39 |
| more common | 0.37 |
| curable | 0.27 |
| common | 0.27 |
| incurable | 0.25 |
| individual | 0.23 |
| fatal | 0.21 |
| contagious | 0.16 |
| chronic disease | 0.60 |
| disease | 0.59 |
| autoimmune disease | 0.59 |
| progressive disease | 0.46 |
| neurological disease | 0.46 |
| debilitating disease | 0.43 |
| inflammatory disease | 0.43 |
| demyelinating disease | 0.40 |
| neurodegenerative disea… | 0.37 |
| central nervous system … | 0.33 |
| More » |
| diagnosed | 0.56 |
| characterized by demyel… | 0.37 |
| difficult to diagnose | 0.36 |
| suspected | 0.36 |
| identified by a genomew… | 0.33 |
| treated | 0.33 |
| categorized by bouts of… | 0.30 |
| treated with fingolimod | 0.28 |
| characterized by muscle… | 0.25 |
| common in canada | 0.25 |
| More » |